Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for inflammatory respiratory disease therapy verekitug.
Amgen and AstraZeneca have said their severe asthma therapy Tezspire could have a role to play in chronic obstructive pulmonary disease (COPD) – a key target indication fo
New start-up Uniquity Bio arrived on the scene today with $300 million in funding from Blackstone Life Sciences and a clinical-stage inflammation and immunology drug licen
GSK has taken another step towards rebuilding its respiratory pipeline with a $1.4 billion agreement to buy Aiolos Bio and its lead drug AIO-001 for asthma and other indic
AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves.
The European Commission has followed the lead of the US FDA and approved AstraZeneca's Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only